Ad­vo­cates call on Vi­iV to low­er price of long-act­ing HIV in­jectable

More than 70 ad­vo­cates — rang­ing from ac­tors to CEOs — signed a let­ter to Vi­iV chief ex­ec­u­tive Deb­o­rah Wa­ter­house on Tues­day re­quest­ing a low­er price for the com­pa­ny’s long-act­ing HIV in­jectable for pre-ex­po­sure pro­phy­lax­is (PrEP) Apre­tude.

The let­ter, pub­lished by the Joint Unit­ed Na­tions Pro­gramme on HIV/AIDS, ar­gues that Apre­tude should be priced “as close as pos­si­ble to that of oth­er HIV pre­ven­tion med­i­cines,” or around $60 per year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER